Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

NCT04982224 | Terminated Phase 1 FDA Drug

• 2 other identifiers: R5093-M114-ONC-18642020-005065-14
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 11

Brief Summary

This study is researching an experimental drug called REGN5093-M114 by itself and in combination with cemiplimab. The study is focused on advanced non-small cell lung cancer (NSCLC) that produces too much of a protein called mesenchymal epithelial transition factor (MET) on the cancer cell surface. The aim of the study is to see how safe, tolerable, and effective the study drug is. This study will include 3 study groups, or cohorts, and each group is split into 2 parts: Part 1: The main purpose of part 1 is to determine a safe dose of REGN5093-M114 (Cohorts A and B), and in combination with cemiplimab (Cohort C). Part 2: The main purpose of part 2 is to use the REGN5093-M114 dose found for each cohort in part 1 to see how well the study drug works to shrink tumors. The study is looking at several other research questions, including:

• What side effects may happen from receiving the study drug
• Does the study drug work to reduce or delay the progression of your cancer
• How much study drug is in the blood at different times
• Does the body make antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

Advanced NSCLC

Keywords

Non-small cell lung cancer; Mesenchymal epithelial transition factor (MET); MET Overexpressing Advanced Cancer

Outcome Measures

Primary Outcomes (11)

• Dose limiting toxicities (DLTs)

  Dose escalation (Phase 1)

  Up to 28 days

• Treatment-emergent adverse events (TEAEs)

  Dose escalation (Phase 1)

  Through study completion, an average of 2 years

• Serious adverse events (SAEs)

  Dose escalation (Phase 1)

  Through study completion, an average of 2 years

• TEAEs leading to study treatment discontinuation

  Dose escalation (Phase 1)

  Through study completion, an average of 2 years

• TEAEs leading to death

  Dose escalation (Phase 1)

  Through study completion, an average of 2 years

• Laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE])

  Dose escalation (Phase 1)

  Through study completion, an average of 2 years

• Concentrations of REGN5093-M114 in serum

  Dose escalation (Phase 1)

  Through study completion, an average of 2 years

• Total monoclonal antibodies (REGN5093- M114 plus unconjugated antibody) in serum

  Dose escalation (Phase 1)

  Through study completion, an average of 2 years

• Concentrations of M24 in plasma

  Dose escalation (Phase 1)

  Through study completion, an average of 2 years

• Concentrations of cemiplimab when given in combination with REGN5093-M114

  Dose escalation (Phase 1) Cohort C

  Through study completion, an average of 2 years

• Objective response rate (ORR)

  Dose expansion (Phase 2)

  Through study completion, an average of 2 years

Secondary Outcomes (21)

• ORR

  Through study completion, an average of 2 years

• TEAEs

  Through study completion, an average of 2 years

• SAEs

  Through study completion, an average of 2 years

• TEAEs leading to study treatment discontinuation

  Through study completion, an average of 2 years

• TEAEs leading to death

  Through study completion, an average of 2 years

Study Arms (2)

Phase 1. Dose Escalation

EXPERIMENTAL

Cohorts A and B: REGN5093-M114 monotherapy. Cohort C: REGN5093-M114+cemiplimab combination.

Drug: REGN5093-M114; Drug: Cemiplimab

Phase 2. Dose Expansion

EXPERIMENTAL

Cohorts A and B: REGN5093-M114 monotherapy. Cohort C: REGN5093-M114+cemiplimab combination.

Drug: REGN5093-M114; Drug: Cemiplimab

Interventions

REGN5093-M114 DRUG

Administered by intravenous (IV) infusion

Phase 1. Dose Escalation; Phase 2. Dose Expansion

Cemiplimab DRUG

Administered by IV infusion

Phase 1. Dose Escalation; Phase 2. Dose Expansion

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically confirmed NSCLC that is at advanced stage for which there are no approved therapies available expected to confer clinical benefit as defined in the protocol
• Willing to provide tumor tissue from newly obtained biopsy from tumor site. Newly obtained biopsies at tissue screening are required. An archival sample can be accepted only after discussion with the medical monitor and if the sample is not more than 6 months old and was obtained on the treatment regimen prior to study screening or after completion of the last therapy. The enrollment of patients will be based on an immunohistochemistry (IHC)-based assay using freshly obtained tumor biopsies or an archival biopsy as described above. Only patients with MET overexpressing tumors by central IHC analysis will be enrolled. For expansion cohorts only: tumor site for biopsy must not have been irradiated previously and must not be the only measurable lesion.
• Tumor must overexpress MET protein as defined in the protocol
• For expansion only: At least one lesion that is measurable by RECIST 1.1. Tumor lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions after radiation.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Adequate organ and bone marrow function as defined in the protocol

You may not qualify if:

• Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device within 2 weeks or 5 half-lives of the prior treatment, whichever is shorter with a minimum of 7 days from the first dose of study therapy
• Has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities resulting from prior therapy except as described in the protocol
• Has received radiation therapy or major surgery within 14 days of first administration of study drug or has not recovered from adverse events as defined in the protocol
• Another malignancy that is progressing or requires active treatment except as noted in the protocol
• Untreated or active primary brain tumor, central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
• Encephalitis, meningitis, organic brain disease (eg Parkinson's disease) or uncontrolled seizures in the year prior to first dose of study therapy
• Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection; or diagnosis of immunodeficiency as defined in the protocol

Sponsors & Collaborators

• Regeneron Pharmaceuticals: lead

Study Sites (11)

University of California Irvine School of Medicine - Suite 400, Room 407

Orange, California, 92868, United States

Location

University of Colorado Hospital Anshutz Outpatient Pavillion

Denver, Colorado, 80045, United States

Location

Johns Hopkins Hospital - Clinical Study Location - Skip Viragh Outpatient Cancer Building

Baltimore, Maryland, 21231, United States

Location

Sidney Kimmel Comprehensive Cancer Center - 4F Second Medical Building

Baltimore, Maryland, 21231, United States

Location

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

Location

Henry Ford Hospital, Henry Ford Cancer Institute

Detroit, Michigan, 48202, United States

Location

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Location

University of Pittsburgh Medical Center - Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States

Location

MUSC Hollings Cancer Center

Charleston, South Carolina, 29425, United States

Location

The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Next Virginia

Fairfax, Virginia, 22031, United States

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

cemiplimab

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Clinical Trial Management

  Regeneron Pharmaceuticals

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 20, 2021
• First Posted: July 29, 2021
• Study Start: November 9, 2021
• Primary Completion: October 15, 2025
• Study Completion: October 15, 2025
• Last Updated: November 3, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
• Time Frame: When Regeneron has: * received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development * made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) * the legal authority to share the data, and * ensured the ability to protect participant privacy.
• Access Criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Locations

US (11)